Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: A multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus

Epilepsia

Volumn 40, Issue SUPPL. 6, 1999, Pages s57-s59

  Backonja, Misha Miroslav ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Diabetes mellitus; Gabapentin; Monotherapy; Neuropathy; Pain

Indexed keywords

GABAPENTIN;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOOD; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SLEEP TIME; VERTIGO;

EID: 0032856480     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb00934.x     Document Type: Conference Paper

References (7)

1. Synopsis of: Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280: 1831-6.
2. Johnson PC, Doll SC, Cromey DW. Pathogenesis of diabetic neuropathy. Ann Neurol 1986;19:450-7.
3. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care 1978;1:168-88, 252-63.
4. Melzack R. The Short-Form McGill Pain Questionnaire. Pain 1987;30:191-7.
5. Neurontin prescribing information. In: Physicians' desk reference. Montvale, NJ: Medical Economics, 1995:1856-8.
6. Ware JE Jr, Snow KK, Konsinski M, Gandek B. SF-36 Health Survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center, 1993.
7. McNair DM, Lorr M, Droppleman LF. Profile of Mood States: manual. San Diego, CA: Educational and Industrial Testing Service, 1981.